Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kelly Van Epps

Diagnostic Radiology Tampa, FL Medical Doctor

NPI 1366417610 CMS profile 334407

4516 N Armenia Ave, Tampa, FL 33603

Open in the dashboard

General payments

$23,203

450 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Van Epps of Tampa, FL is reported in the CMS Open Payments database as having received $23,203 across 450 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,690 140
2024 General $4,666 92
2023 General $3,962 60
2022 General $2,720 61
2021 General $2,914 43
2020 General $1,468 24
2019 General $2,784 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Van Epps
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Kelly Van Epps were reported at $4,690. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Kelly Van Epps Diagnostic Radiology median Middle half National median
2019 $2,784 $108 $29–$318 $163
2020 $1,468 $65 $21–$252 $114
2021 $2,914 $92 $24–$292 $132
2022 $2,720 $104 $29–$294 $149
2023 $3,962 $110 $29–$337 $160
2024 $4,666 $113 $30–$356 $164
2025 $4,690 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inari Medical, Inc. $7,279 106 payments
  2. Penumbra, Inc. $4,659 49 payments
  3. Imperative Care, INc $3,291 56 payments
  4. Boston Scientific Corporation $1,326 27 payments
  5. AngioDynamics, Inc. $982 13 payments
  6. Stryker Corporation $966 65 payments
  7. Terumo Medical Corporation $948 12 payments
  8. Cook Medical LLC $730 24 payments
  9. Medtronic, Inc. $558 21 payments
  10. DePuy Synthes Sales Inc. $471 17 payments
  11. Other $1,993 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,466 436 payments
  2. Travel and Lodging $2,637 13 payments
  3. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $7,770 128 payments
  2. CT THROMBECTOMY SYSTEM KIT $7,176 120 payments
  3. Indigo System $2,518 33 payments
  4. SYMPHONY CATHETER $2,391 36 payments
  5. Indigo $1,492 6 payments
  6. Navicross $877 8 payments
  7. OBSIDIO $688 8 payments
  8. ZOOM 88-T LARGE DISTAL PLATFORM $509 9 payments
  9. EMBOLD Fibered $418 9 payments
  10. SIR-Spheres Microspheres $367 8 payments
  11. Other $6,183 205 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

30

Median for Diagnostic Radiology: 24

Drug cost

$34

Median for Diagnostic Radiology: $190

Branded share of claims

0%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisone Generic 30 $34

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 249 billing codes

Paid by Medicare

$102,734

Of which drugs: $802

Medicare patients

1,279

Average age 76

Services billed

9,632

733 women, 546 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Ischemic heart disease 56%
Chronic kidney disease 47%
Diabetes 45%
Depression 42%
Heart failure 39%
Atrial fibrillation 37%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 84 7,711 $787

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

450 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record